Takeda Pharmaceutical Company Limited Discusses Global Strategic Collaboration for Next-Generation Oncology Assets and ADC Molecules

Takeda Pharmaceutical Company Limited has announced a global strategic collaboration with Innovent for next-generation oncology assets and ADC molecules. The collaboration aims to enhance the companies' oncology pipelines and expand their global reach. Innovent's CEO, Dr. Michael Yu, will present an update on the company's globalization strategy, followed by CBO Dr. Samuel Zhang, who will review the partnership arrangement and introduce Takeda as the partner. Dr. Hui Zhou will present details on the programs in the collaboration. A Q&A session will follow, during which Dr. P.K. Morrow will join the discussion.